Authors

Designing for Safety: The Pharma Industry’s Role in Preventing Medication Errors

Pharmaceutical companies must consider formulation, packaging, and labeling from the start to minimize errors and protect patients.

Caffeine vs Guarana: Can AI Predict Which Stimulant Packs the Bigger Punch?

AI-driven analysis reveals guarana offers more sustained cognitive stimulation than caffeine, due to additional bioactive compounds and slower caffeine release kinetics.

Pharmacists Can Advance Lung Cancer Screening Awareness in High-Risk Patients

Pharmacists can help close the lung cancer screening gap by identifying high-risk tobacco users, increasing awareness, and connecting eligible patients to lifesaving early detection.

Pharmacists Can Help Patients Navigate GLP-1 Access, Affordability, and Long-Term Use

In an interview with Pharmacy Times, Deanna Horner, PharmD, BCPS, executive vice president of Eversona Enterprise Direct Strategy, discussed how payers, employers, and health plans can approach GLP-1 coverage as demand for these therapies continues to grow.

Pharmacists’ Role in Antibiotic Stewardship: Understanding Spectrums to Combat Resistance

Pharmacists ensure responsible antibiotic use, combating resistance through tailored therapies.

340B's Next Era: Why Hospitals Must Pair Compliance With Measurable Quality Outcomes

The future of 340B depends on integrating quality, compliance, technology, and pharmacist-led care to improve patient outcomes and strengthen audit readiness.

The Pharmacist’s Role in Managing High-Risk MS Patients

In an interview with Pharmacy Times at the Consortium of Multiple Sclerosis Centers 2026, Stephanie Iyer, PhD, CPP, BCACP, a clinical pharmacist at University of North Carolina neurology clinic, presenting on management of High-risk multiple sclerosis patients, discussed what the pharmacist's role is in managing high-risk MS patients.

Pharmacists and Continuous Glucose Monitoring: An Attachment Worth Having

Study authors suggest diabetic guidelines should consider standardized reporting of CGM metrics in studies employing CGM-based interventions.

FAQs on Mifepristone Safety, Access, Current Legislation, and the Pharmacist’s Role

This FAQ covers current dispensing regulations, practical considerations for pharmacists, and the clinical pharmacology of mifepristone.

RSV in Older Adults: The More You Know, the Better Off Your Patients Will Be

Respiratory syncytial virus hits older adults hard and is often missed. Learn symptoms, testing, and how new vaccines and pharmacists help prevent severe illness.

Evaluating Iron Sucrose Discordance: A Retrospective Health System Review

After transitioning iron sucrose 200 mg from an infusion to intravenous push, the incidence of discordance and infusion reactions were not statistically different.

From the Pharmacy Counter to the Kitchen Cabinet: Helping Patients Choose Quality Supplements

Pharmacists guide consumers in selecting quality dietary supplements, emphasizing the importance of USP verification for safety and efficacy.

Heal or Harm: Body Protective Compound-157 in the Gray Zone

Only 3 uncontrolled pilot studies with a combined sample size of 30 participants have been reported for BPC-157.

OTC Case Studies: Supplements for Aging

Explore essential supplement recommendations for older adults, including vitamin D, calcium, melatonin, and multivitamins, to enhance health and well-being.

FDA Approves Dolutegravirfor HIV Treatment in Newborns

The FDA has expanded the approval of dolutegravir expands access to a second-generation integrase inhibitor for infants in the neonatal period.

Understanding The Independent Pharmacy Data Economy

Independent pharmacies are being squeezed on reimbursement while their data quietly fuels billion-dollar decisions. A new pharmacy data economy could flip that script.

School of Pharmacy Duo Places Second in National Clinical Skills Competition

MHC Class II Peptide Binding Prediction: Challenges, AlphaFold 3, and ESM2 Explained

Pharmacy Times interviews Kamel Lahouel, PhD, and Cristian Tomasetti, PhD, on the challenges of predicting MHC class II peptide binding and how combining structural and sequence-based models can improve accuracy while addressing key limitations.

The Controversial 340B Rebate Pilot Program Is Moving Forward

HRSA moves forward with the 340B Rebate Model Pilot Program, raising concerns among health care providers about financial impacts and operational challenges.

Study Reveals Virtual Reality Effectively Educates Pharmacists on Continuous Glucose Monitors

Community pharmacists are uniquely positioned to assist with diabetes management using CGM devices.

The July Spike in Ordering Errors: A Call for Proactive Pharmacy Involvement

Pharmacists play a critical role in preventing medication ordering errors during residency onboarding through proactive training, system safeguards, and interdisciplinary collaboration.

Staying in the Know: Pharmacists, Drug Shortages, and What Lies Ahead

Pharmacists should be aware of current discussions, attempted fixes, and expected length of drug shortages.

Clearing the Air: The Influence of Vaping on Smoking Cessation

Pharmacists can help address nicotine addiction by recommending FDA-approved smoking cessation methods and educating on the risks associated with electronic cigarette use.

Single-Center Experience With Vorasidenib in Patients With Grade 3 or 4 IDH-Mutant Gliomas

This abstract was presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 18 to 19, 2026.

The Expanding Role of CDK 4/6 Inhibitors in Breast Cancer Treatment

Cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors have transformed the treatment of hormone receptor-positive/HER2-negative breast cancer across metastatic and early-stage settings, with ongoing research exploring their potential in additional breast cancer subtypes, combination therapies, and aggressive disease scenarios.

Medetomidine in the Illicit Drug Supply: What Pharmacists Need to Know About "Rhino Tranq" and Naloxone-Resistant Overdoses

As medetomidine rapidly displaces xylazine as a fentanyl adulterant, pharmacists must recognize its distinct toxidrome, understand why naloxone alone is insufficient, and support updated harm reduction strategies in an increasingly complex overdose landscape.

Bortezomib Off-Week Regimen Shows Promise for Reducing Toxicity in Multiple Myeloma

Erin Harrell, PharmD, offers insights about managing peripheral neuropathy in patients receiving bortezomib.

Impact of Time to First Epinephrine Administration on Outcomes After In-Hospital Cardiac Arrest With Initial Nonshockable Rhythm

This study found no significant difference in the sustained return of spontaneous circulation or survival to hospital discharge based on the timing of the first epinephrine administration in these patients.